Commercial
  
MPNewsFlashTopicPub
MPPurposePub
  
  
  
  
3/1/2021
Coverage of the COVID-19 Vaccination for Independence Members (Updated March 1, 2021)


The purpose of this communication is to provide notice regarding information and procedure codes related to the coverage of SARS-CoV-2 (Corona​virus Disease 2019 (COVID-19)) vaccines and administration of the vaccines for Independence commercial members.

0.1Coverage of the COVID-19 Vaccination for Independence Members (Updated March 1, 2021)17a6a36d-8be0-4777-b3ea-3799831f90ed
1/25/2021
Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Commercial Independence Members (Updated January 25, 2021)

The purpose of this communication is to provide advance notice regarding information and procedure codes related to testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Commercial Independence members.
0Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Commercial Independence Members (Updated January 25, 2021)c7d8aeb1-eeb9-4d5f-88d4-4e16888da081
1/18/2021
Telemedicine Services for Independence Commercial Members (Updated February 10, 2021)
The purpose of this document is to provide advance notice regarding coverage for telemedicine services for our Independence commercial members in response to Coronavirus Disease 2019 (COVID-19).
0.1Telemedicine Services for Independence Commercial Members (Updated February 10, 2021)19bf15e1-7dd8-46e7-9f09-167e87556ed6
1/4/2021
1/1/2021 CPT & HCPCS Annual Code Update Coverage Determinations for Commercial Products
The intent of this document is to communicate Commercial Product coverage determinations for services identified through the Annual Code Update process. 
01/1/2021 CPT & HCPCS Annual Code Update Coverage Determinations for Commercial Productsb976b7b6-ff87-4f04-a559-d2f8805e0586
12/30/2020
Veklury® (remdesivir) (including in combination with Olumiant® (baricitinib)), Bamlanivimab® (LY-CoV555), and Casirivimab/Imdevimab for COVID-19 Treatment of Independence Commercial Members (Updated December 30, 2020)

The purpose of this document is to communicate the Company's coverage position for Veklury® (remdesivir) (including in combination with Olumiant® (baricitinib)), Bamlanivimab® (LY-CoV555), and Casirivimab/Imdevimab for COVID-19 treatment of Independence commercial members. 

This communication addressing Treatments for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) is effective from October 22, 2020 through March 31, 2021, or for the duration of the public health emergency.​

This document includes the following updates to the version that was published on November 25, 2020:

  • The name of this communication was changed FROM Veklury® (remdesivir) and Bamlanivimab® (LY-CoV555) for COVID-19 Treatment TO Veklury® (remdesivir) (including in combination with Olumiant® (baricitinib)), Bamlanivimab® (LY-CoV555), and Casirivimab/Imdevimab for COVID-19 Treatment.
  • Combination of Olumiant® (baricitinib)) and Veklury® (remdesivir) for COVID-19 Treatment, including coverage statement, was addressed per FDA Emergency Use Authorization (EUA) for this combination therapy.
  • Combination of Casirivimab/Imdevimab for COVID-19 Treatment, including coverage statement and procedure codes, was addressed per FDA EUA for this combination therapy.

0Veklury® (remdesivir) (including in combination with Olumiant® (baricitinib)), Bamlanivimab® (LY-CoV555), and Casirivimab/Imdevimab for COVID-19 Treatment of Independence Commercial Members (Updated December 30, 2020)0ea6a489-6b22-4c9a-8a1f-5eea5f0419f2
11/25/2020
Notice of Withdrawal of Advance Notification of Future Policy #00.10.41h: Telemedicine Services (Independence)

The purpose of this communication is to provide notice that Advance Notification of future Policy​ #00.10.41h: Telemedicine Services (Independence)​ has been withdrawn from the Medical Policy Portal.
0Notice of Withdrawal of Advance Notification of Future Policy #00.10.41h: Telemedicine Services (Independence)83a7cfbd-7329-4606-adb9-2f8e7b8ba399
10/1/2020
10/1/2020 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products
The intent of this article is to communicate Commercial Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 10/1/2020, unless otherwise noted.

For more information related to these services, please refer to specific policies when applicable.​

110/1/2020 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Productsc322926f-ec73-4821-aac6-943615dd055a
7/17/2020
Consumer Grade Pulse Oximetry Devices For Use In The Home Setting
The purpose of this News Article is to provide advance notice during the COVID-19 outbreak related to the coverage of consumer grade pulse oximetry devices for use in the home setting.
1Consumer Grade Pulse Oximetry Devices For Use In The Home SettingC8D6FA9AF15929A88525857E004FAA79
7/17/2020
Respiratory Equipment and Related Supplies (updated July 17, 2020)
The purpose of this News Article is to provide advance notice during the COVID-19 outbreak related to respiratory equipment and related supplies.
1Respiratory Equipment and Related Supplies (updated July 17, 2020)A957C168AD6F9248852585A700776FBF
7/1/2020
7/1/2020 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products
17/1/2020 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products5D38243F686BE26685258598006308EB
1 - 10Next